Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 103-116, February 2009

Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders

  • André J. Scheen, MD, PhD (Professor and Doctor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +32 4 3667238; Fax: +32 4 3667068.
    • ,
  • Nicolas Paquot, MD, PhD (Professor and Doctor)

Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman (B35), University of Liège, B 4000 Liège, Belgium

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-690X(08)00098-5

doi:10.1016/j.beem.2008.09.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 103-116, February 2009

Article Tools

* Image Usage & Resolution